RxDoctor Payments Data

Subramaniam Krishnamurthi, MD

Cardiology · Sapulpa, OKNPI 1164421343

Payments from drug & device makers

$3,487in general payments, 2019–2025

Across 49 payments — averaging $71.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$741
  • Boehringer Ingelheim$607
  • Lilly USA, LLC$337
  • Johnson & Johnson$152
  • Bayer$128
  • plus $438 from 6 others

What the payments were for

  • Food & beverage$3,44799%
  • Education$401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in Oklahomato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$21,811
Medicare patients
46
Services billed
279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide33$42,925
EliquisApixaban44$33,704
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$24,355
JardianceEmpagliflozin13$20,164
TradjentaLinagliptin20$13,766
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,095
LinzessLinaclotide12$10,756
Tresiba Flextouch U-100Insulin Degludec13$9,997
XareltoRivaroxaban13$6,903
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,720
Novolog FlexpenInsulin Aspart13$3,398
Atorvastatin Calcium176$2,965
Ventolin HfaAlbuterol Sulfate32$2,784
Omeprazole105$2,393
Albuterol Sulfate HfaAlbuterol Sulfate82$2,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$741$42,92533 claims
Boehringer IngelheimJardiance, Tradjenta$607$33,92933 claims
PfizerEliquis$12$33,70444 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,086$30,07548 claims
AstraZenecaBreztri Aerosphere$125$11,09517 claims
Johnson & JohnsonXarelto$152$6,90313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Oklahomaon file to place this against a meaningful peer group, so we don't.

Other cardiology in Sapulpa

Where these figures come from

Is this you, or does something look wrong? →